Alkahest, Inc.
Plasma-derived therapeutic candidates identified through AI-driven multiomics analysis
- Sector
- Biotech
- Headquarters
- REDWOOD CITY, CA
- Founded
- 2014
- Latest Form D
- $3.5M, Aug 2014
- Total capital
- $3.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $3.5M
- 1 Form D · last Aug 2014
- 147 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 25
- 15 pending · first 2020
- Rank in peer group#62 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$3.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#62 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anton Wyss-CorayDirectorNamed in SEC Form D filings
- Karoly NikolichExecutive Officer, DirectorNamed in SEC Form D filings
- Tamara KentExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 25 granted of 40- New patentUse of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative RecoveryUSPTOUS 12,758,581
- PendingBlood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersUSPTOApplication 19633446
- GrantedBlood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersUSPTOUS 12,697,373
Show all 40 patent records
- Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative RecoveryOct 13, 2026 · US 12,758,581Granted
- Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersSep 17, 2026 · Application 19633446Pending
- Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersAug 4, 2026 · US 12,697,373Granted
- Methods Of Improving Retina-associated Disease Outcome Using CCR3-INHIBITORSJul 28, 2026 · US 12,692,301Granted
- Benzodioxane Modulators of Leukotriene A4 Hydrolase (LTA4H) for Prevention and Treatment of Aging-Associated DiseasesDec 16, 2025 · US 12,496,296Granted
- Blood Plasma Fractions for Use in Muscle RegenerationOct 31, 2024 · Application 18766239Pending
- Blood Plasma Fractions for Use in Liver RegenerationOct 17, 2024 · Application 18753638Pending
- Blood Plasma Fractions for Use in Muscle RegenerationAug 13, 2024 · US 12,059,453Granted
- Blood Plasma Fractions for Use in Liver RegenerationAug 6, 2024 · US 12,053,489Granted
- Benzodioxane Modulators of Leukotriene A4 Hydrolase (LTA4H) for Prevention and Treatment of Aging-Associated DiseasesApr 16, 2024 · US 11,957,671Granted
- Methods And Compositions For Treating Retina-associated Disease Using CCR3-INHIBITORSApr 9, 2024 · US 11,951,102Granted
- Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 ModulatorsMar 7, 2024 · Application 18272007Pending
- Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-InhibitorsNov 2, 2023 · Application 18119522Pending
- Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative RecoverySep 14, 2023 · Application 18199652Pending
- Methods of Inducing Liver Regeneration by Administering a Plasma Protein FractionMay 30, 2023 · US 11,660,316Granted
- Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative RecoveryApr 13, 2023 · Application 18075805Pending
- Pharmaceutical Formulations Comprising CCR3 AntagonistsMar 28, 2023 · US 11,612,596Granted
- Methods And Compositions For Treating Retina-associated Disease Using CCR3-INHIBITORSFeb 28, 2023 · US 11,590,118Granted
- Methods of Treating a Subject for PainJan 10, 2023 · US 11,547,724Granted
- Method Of Treating Liver Failure With Plasma Fraction IV-4Nov 1, 2022 · US 11,484,551Granted
- Blood Plasma Fractions for Use in Muscle RegenerationSep 13, 2022 · US 11,439,687Granted
- Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 HydrolaseAug 30, 2022 · US 11,426,399Granted
- Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma ProductsAug 16, 2022 · US 11,413,308Granted
- Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 HydrolaseJul 21, 2022 · Application 17700804Pending
- Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-InhibitorsJul 12, 2022 · US 11,382,907Granted
- Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 HydrolaseMay 31, 2022 · US 11,344,542Granted
- Methods of Improving Wound HealingApr 12, 2022 · US 11,298,377Granted
- Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma ProductsOct 14, 2021 · Application 17323664Pending
- Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 ModulatorsSep 30, 2021 · Application 17318875Pending
- Methods of Improving or Accelerating Postoperative RecoveryAug 31, 2021 · US 11,103,530Granted
- Methods For Screening Human Blood Products Comprising Plasma Using Immunocompromised Rodent ModelsAug 5, 2021 · Application 17153601Pending
- Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma ProductsJun 22, 2021 · US 11,040,068Granted
- Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 ModulatorsJun 10, 2021 · Application 17104344Pending
- Blood Plasma and Plasma Fractions as Therapy for Tumor Growth and ProgressionApr 22, 2021 · Application 17132772Pending
- Blood Plasma and Plasma Fractions as Therapy for Tumor Growth and ProgressionFeb 2, 2021 · US 10,905,717Granted
- Methods For Screening Human Blood Products Comprising Plasma Using Immunocompromised Rodent ModelsFeb 2, 2021 · US 10,905,779Granted
- Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma ProductsDec 29, 2020 · US 10,874,692Granted
- Use of CCR3-InhibitorsDec 3, 2020 · Application 16997772Pending
- Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-InhibitorsFeb 20, 2020 · Application 16582933Pending
- Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersJan 7, 2020 · US 10,525,107Granted
Related companies, and why
- Angiex, Inc.Similar federal contract value in Biotech · null in contracts
- SpringWorks TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ALAMAB THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Evercrisp Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Intrommune Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Entheos Labs, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .